Expertise in
15
conditions

Dr. Ara D. Metjian

Hematology
Private Diagnostic Clinic PLLC
40 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Private Diagnostic Clinic PLLC
40 Duke Medicine Cir, 
Durham, NC 

Overview

Ara Metjian is a Hematologist practicing medicine in Durham, North Carolina.

Dr. Metjian is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Blood Clots, Thrombotic Thrombocytopenic Purpura, and Pulmonary Embolism.

He is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 5 clinical trials. Dr. Metjian is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in NC

Hospital Affiliations

Duke Regional Hospital
Duke University Hospital

Languages Spoken

English
Armenian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 9 Less Insurance Carriers -

Locations

Private Diagnostic Clinic PLLC
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Apixaban, Warfarin
Study Phase: Phase 4
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
View 4 Less Clinical Trials

26 Total Publications

Proteomics of arterial thrombi in acute limb ischemia.
Proteomics of arterial thrombi in acute limb ischemia.
Journal: Journal of thrombosis and thrombolysis
Published: May 26, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Referral may be required

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (5.6 miles away)
984-974-2695
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Nigel Key is a Hematologist and an Oncologist practicing medicine in Chapel Hill, North Carolina. Dr. Key is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease. Dr. Key is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (21.0 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (21.0 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist practicing medicine in Cary, North Carolina. Dr. Bose is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Ara D. Metjian

How do I make an appointment with Dr. Ara D. Metjian?

You can book an appointment with Dr. Ara D. Metjian by calling their office at 919-684-5350. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ara D. Metjian a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ara D. Metjian is classified as an Distinguished expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ara D. Metjian specialize in?

While Dr. Ara D. Metjian is a Hematology, they have specific expertise in Thrombocytopenia, Blood Clots, and Thrombotic Thrombocytopenic Purpura. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ara D. Metjian participate in research or clinical trials?

Yes. Dr. Ara D. Metjian has published 26 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. Ara D. Metjian's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ara D. Metjian accept my insurance?

Dr. Ara D. Metjian accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 919-684-5350 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Metjian's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile